The Community Guide

- gsearch

Search Results

Narrow Results:

2019 1
2018 1
2015 1
2014 1
2013 2
2005 1

United States 2

Journal Article 7

adverse event 1
cell culture 1
surveillance 1
trivalent inactivated influenza vaccine 1
vaccine safety 1

1 - 7 of 7 Results

Refine Results

Refine Results:

Application of real time RT-PCR for the genetic homogeneity and stability tests of the seed candidates for live attenuated influenza vaccine production

CITE Title : Application of real time RT-PCR for the genetic homogeneity and stability tests of the seed candidates for live attenuated influenza vaccine production Personal Author(s) : Shcherbik, Svetlana;Sergent, Sheila B.;Davis, William G.;Shu, Bo;Barnes, John;Kiseleva, Irina;Larionova, Natalie;Klimov, Alexander;Bousse, Tatiana; Published Date : September 18 2013 Source : J Virol Methods. 195:18-25 URL : https://stacks.cdc.gov/view/cdc/34984 Shcherbik, Svetlana et al. (2013). Application of real time RT-PCR for the genetic homogeneity and stability tests of the seed candidates for live attenuated influenza vaccine production. 195 Shcherbik, Svetlana et al. "Application of real time RT-PCR for the genetic homogeneity and stability tests of the seed candidates for live attenuated influenza vaccine production" 195 (2013) Shcherbik, Svetlana et al. "Application of real time RT-PCR for the genetic homogeneity and stability tests of the seed candidates for live attenuated influenza vaccine production" vol. 195, 2013 Export RIS Citation Information.

:

Shcherbik, Svetlana ;

Sergent, Sheila B.

September 18 2013 | J Virol Methods. 195:18-25

:

Development and improvement of quality control tests for live attenuated vaccines are a high priority because of safety concerns. Live attenuated infl...
Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2009–2012

CITE Title : Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2009–2012 Personal Author(s) : Rabe, Ingrid B.;Miller, Elaine R.;Fischer, Marc;Hills, Susan L.; Published Date : Dec 09 2014 Source : Vaccine. 33(5):708-712. URL : https://stacks.cdc.gov/view/cdc/50867 Rabe, Ingrid B. et al. (2014). Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2009–2012. 33(5). Rabe, Ingrid B. et al. "Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2009–2012" 33, no. 5 (2014) Rabe, Ingrid B. et al. "Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2009–2012" vol. 33, no. 5, 2014 Export RIS Citation Information.

:

Rabe, Ingrid B. ;

Miller, Elaine R.

Dec 09 2014 | Vaccine. 33(5):708-712.

:

BackgroundIn March 2009, the U.S. Food and Drug Administration licensed an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC...
Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2012–2016

CITE Title : Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2012–2016 Personal Author(s) : Walker, William L.;Hills, Susan L.;Miller, Elaine R.;Fischer, Marc;Rabe, Ingrid B.; Published Date : 7-05- Source : Vaccine. 36(29):4369-4374 URL : https://stacks.cdc.gov/view/cdc/114864 Walker, William L. et al. (2005). Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2012–2016. 36(29). Walker, William L. et al. "Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2012–2016" 36, no. 29 (2005) Walker, William L. et al. "Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2012–2016" vol. 36, no. 29, 2005 Export RIS Citation Information.

:

Walker, William L. ;

Hills, Susan L.

7-05- | Vaccine. 36(29):4369-4374

:

Background:In March 2009, the U.S. Food and Drug Administration licensed an inactivated Vero cell culture-derived Japanese encephalitis vaccine (JE-VC...
Genetic and Phenotypic Characterization of Manufacturing Seeds for a Tetravalent Dengue Vaccine (DENVax)

CITE Title : Genetic and Phenotypic Characterization of Manufacturing Seeds for a Tetravalent Dengue Vaccine (DENVax) Personal Author(s) : Huang, Claire Y.-H.;Kinney, Richard M.;Livengood, Jill A.;Bolling, Bethany;Arguello, John J.;Luy, Betty E.;Silengo, Shawn J.;Boroughs, Karen L.;Stovall, Janae L.;Kalanidhi, Akundi P.;Brault, Aaron C.;Osorio, Jorge E.;Stinchcomb, Dan T.; Published Date : May 2013 Source : PLoS Neglected Tropical Diseases. 2013; 7(5). URL : https://stacks.cdc.gov/view/cdc/13649 Huang, Claire Y.-H. et al. (2013). Genetic and Phenotypic Characterization of Manufacturing Seeds for a Tetravalent Dengue Vaccine (DENVax). 7(5). Huang, Claire Y.-H. et al. "Genetic and Phenotypic Characterization of Manufacturing Seeds for a Tetravalent Dengue Vaccine (DENVax)" 7, no. 5 (2013) Huang, Claire Y.-H. et al. "Genetic and Phenotypic Characterization of Manufacturing Seeds for a Tetravalent Dengue Vaccine (DENVax)" vol. 7, no. 5, 2013 Export RIS Citation Information.

:

Huang, Claire Y.-H. ;

Kinney, Richard M.

May 2013 | PLoS Neglected Tropical Diseases. 2013; 7(5).

:

BackgroundWe have developed a manufacturing strategy that can improve the safety and genetic stability of recombinant live-attenuated chimeric dengue ...
Monoclonal antibody against N2 neuraminidase of cold adapted A/Leningrad/134/17/57 (H2N2) enables efficient generation of live attenuated influenza vaccines

CITE Title : Monoclonal antibody against N2 neuraminidase of cold adapted A/Leningrad/134/17/57 (H2N2) enables efficient generation of live attenuated influenza vaccines Personal Author(s) : Shcherbik, Svetlana;Carney, Paul;Pearce, Nicholas;Stevens, James;Dugan, Vivien G.;Wentworth, David E.;Bousse, Tatiana; Published Date : July 12 2018 Source : Virology. 522:65-72 URL : https://stacks.cdc.gov/view/cdc/78336 Shcherbik, Svetlana et al. (2018). Monoclonal antibody against N2 neuraminidase of cold adapted A/Leningrad/134/17/57 (H2N2) enables efficient generation of live attenuated influenza vaccines. 522 Shcherbik, Svetlana et al. "Monoclonal antibody against N2 neuraminidase of cold adapted A/Leningrad/134/17/57 (H2N2) enables efficient generation of live attenuated influenza vaccines" 522 (2018) Shcherbik, Svetlana et al. "Monoclonal antibody against N2 neuraminidase of cold adapted A/Leningrad/134/17/57 (H2N2) enables efficient generation of live attenuated influenza vaccines" vol. 522, 2018 Export RIS Citation Information.

:

Shcherbik, Svetlana ;

Carney, Paul

July 12 2018 | Virology. 522:65-72

:

Cold adapted influenza virus A/Leningrad/134/17/57 (H2N2) is a reliable master donor virus (Len/17-MDV) for preparing live attenuated influenza vaccin...
Surveillance of Adverse Events After the First Trivalent Inactivated Influenza Vaccine Produced in Mammalian Cell Culture (Flucelvax®) Reported to the Vaccine Adverse Event Reporting System (VAERS), United States, 2013-2015

CITE Title : Surveillance of Adverse Events After the First Trivalent Inactivated Influenza Vaccine Produced in Mammalian Cell Culture (Flucelvax®) Reported to the Vaccine Adverse Event Reporting System (VAERS), United States, 2013-2015 Personal Author(s) : Moro, Pedro L.;Winiecki, Scott;Lewis, Paige;Shimabukuro, Tom T.;Cano, Maria; Published Date : 11 27 2015;11-27-; Source : Vaccine. 33(48):6684-6688 URL : https://stacks.cdc.gov/view/cdc/78347 Moro, Pedro L. et al. (2015). Surveillance of Adverse Events After the First Trivalent Inactivated Influenza Vaccine Produced in Mammalian Cell Culture (Flucelvax®) Reported to the Vaccine Adverse Event Reporting System (VAERS), United States, 2013-2015. 33(48). Moro, Pedro L. et al. "Surveillance of Adverse Events After the First Trivalent Inactivated Influenza Vaccine Produced in Mammalian Cell Culture (Flucelvax®) Reported to the Vaccine Adverse Event Reporting System (VAERS), United States, 2013-2015" 33, no. 48 (2015) Moro, Pedro L. et al. "Surveillance of Adverse Events After the First Trivalent Inactivated Influenza Vaccine Produced in Mammalian Cell Culture (Flucelvax®) Reported to the Vaccine Adverse Event Reporting System (VAERS), United States, 2013-2015" vol. 33, no. 48, 2015 Export RIS Citation Information.

:

Moro, Pedro L. ;

Winiecki, Scott

11 27 2015 | Vaccine. 33(48):6684-6688

:

Background:In November 2012, the first cell cultured influenza vaccine, a trivalent subunit inactivated influenza vaccine (Flucelvax®, ccIIV3), was a...
Meeting report: 32nd International Conference on Antiviral Research

CITE Title : Meeting report: 32nd International Conference on Antiviral Research Personal Author(s) : Tramontano, Enzo;Tarbet, Bart;Spengler, Jessica R.;Seley-Radtke, Katherine;Meier, Chris;Jordan, Robert;Janeba, Zlatko;Gowen, Brian;Gentry, Brian;Esté, José A.;Bray, Mike;Andrei, Graciela;Schang, Luis M.; Published Date : 9 2019 Source : Antiviral Res. 169:104550 URL : https://stacks.cdc.gov/view/cdc/86261 Tramontano, Enzo et al. (2019). Meeting report: 32nd International Conference on Antiviral Research. 169 Tramontano, Enzo et al. "Meeting report: 32nd International Conference on Antiviral Research" 169 (2019) Tramontano, Enzo et al. "Meeting report: 32nd International Conference on Antiviral Research" vol. 169, 2019 Export RIS Citation Information.

:

Tramontano, Enzo ;

Tarbet, Bart

9 2019 | Antiviral Res. 169:104550

:

The 32nd International Conference on Antiviral Research (ICAR), sponsored by the International Society for Antiviral Research (ISAR), was held in Balt...